Martin A Walter

Summary

Publications

  1. ncbi request reprint Situs inversus completus
    M A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 30:1202. 2003
  2. doi request reprint Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models
    M A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    Eur J Clin Invest 39:51-7. 2009
  3. doi request reprint Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    Cancer 116:31-40. 2010
  4. ncbi request reprint The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 48:1620-5. 2007
  5. ncbi request reprint [(18)F]fluorodeoxyglucose PET in large vessel vasculitis
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, Basel CH 4031, Switzerland
    Radiol Clin North Am 45:735-44, viii. 2007
  6. doi request reprint Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice
    Martin A Walter
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
    J Nucl Med 51:1285-92. 2010
  7. pmc Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Switzerland
    BMJ 334:514. 2007
  8. ncbi request reprint Coregistered iodine-131 single photon emission computed tomography/computed tomography reveals dedifferentiation in a metastatic follicular thyroid carcinoma
    Martin A Walter
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel, Switzerland
    Thyroid 16:1063-4. 2006
  9. ncbi request reprint Extraction of high-integrity RNA suitable for microarray gene expression analysis from long-term stored human thyroid tissues
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Switzerland
    Pathology 38:249-53. 2006
  10. ncbi request reprint Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 33:730-7. 2006

Detail Information

Publications35

  1. ncbi request reprint Situs inversus completus
    M A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 30:1202. 2003
  2. doi request reprint Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models
    M A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    Eur J Clin Invest 39:51-7. 2009
    ....
  3. doi request reprint Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    Cancer 116:31-40. 2010
    ..Procalcitonin has been well established as an important marker of sepsis and systemic infection. The authors evaluated the diagnostic and predictive value of calcitonin and its prohormone procalcitonin in medullary thyroid cancer...
  4. ncbi request reprint The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 48:1620-5. 2007
    ..The long-term dental safety profile of high-dose radioiodine therapy remained elusive despite more than 6 decades of clinical use...
  5. ncbi request reprint [(18)F]fluorodeoxyglucose PET in large vessel vasculitis
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, Basel CH 4031, Switzerland
    Radiol Clin North Am 45:735-44, viii. 2007
    ..High sensitivity is attained by scanning during the active inflammatory phase. Thus, [18F]FDG-PET has the potential to develop into a valuable tool in the diagnostic workup of giant cell arteritis and Takayasu's arteritis...
  6. doi request reprint Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice
    Martin A Walter
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
    J Nucl Med 51:1285-92. 2010
    ....
  7. pmc Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Switzerland
    BMJ 334:514. 2007
    ..To determine the effect of adjunctive antithyroid drugs on the risk of treatment failure, hypothyroidism, and adverse events after radioiodine treatment...
  8. ncbi request reprint Coregistered iodine-131 single photon emission computed tomography/computed tomography reveals dedifferentiation in a metastatic follicular thyroid carcinoma
    Martin A Walter
    Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel, Switzerland
    Thyroid 16:1063-4. 2006
  9. ncbi request reprint Extraction of high-integrity RNA suitable for microarray gene expression analysis from long-term stored human thyroid tissues
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Switzerland
    Pathology 38:249-53. 2006
    ..Herein, we describe successful extraction of high-integrity RNA from human thyroid tissues that were stored for more than a decade...
  10. ncbi request reprint Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 33:730-7. 2006
    ..By generating three groups with comparable radioiodine uptake, we also investigated whether the effect of carbimazole depends on the radioiodine uptake...
  11. doi request reprint Metabolic imaging allows early prediction of response to vandetanib
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital, Bern, Switzerland
    J Nucl Med 52:231-40. 2011
    ..We therefore hypothesized that metabolic imaging could allow noninvasive detection of response to the RET inhibitor vandetanib in vivo...
  12. ncbi request reprint The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease
    Martin A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 32:674-81. 2005
    ..This study was performed to investigate the value of( 18)F-fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease...
  13. ncbi request reprint Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication: a prospective paired comparison
    M A Walter
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031 Basel, Schweiz
    Nuklearmedizin 44:33-6. 2005
    ....
  14. ncbi request reprint Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome
    M A Walter
    Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    Eur J Clin Invest 34:365-70. 2004
    ..The aim of this study was to analyze the influence of RAI uptake on the outcome after RAI treatment and to estimate uptake-dependent success rates...
  15. pmc Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
    Nicolas Marincek
    Institute of Nuclear Medicine, University Hospital Basel, CH
    J Transl Med 11:17. 2013
    ..We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors...
  16. doi request reprint Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers
    Linda Villard
    University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    J Clin Oncol 30:1100-6. 2012
    ..Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide therapy with a single versus a combination of radioisotopes...
  17. doi request reprint Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective
    Franziska Walter
    Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA
    J Nucl Med 53:393-8. 2012
    ..We investigated the impact of (18)F-DOPA brain PET/CT on the clinical management of patients with known or suspected brain tumors...
  18. doi request reprint Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers
    Anna Imhof
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, Basel, Switzerland
    J Clin Oncol 29:2416-23. 2011
    ..To investigate response, survival, and safety profile of the somatostatin-based radiopeptide (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) in neuroendocrine cancers...
  19. doi request reprint [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial
    Fabienne Iten
    Institute of Nuclear Medicine, University Hospital Basel, Switzerland
    Cancer 115:2052-62. 2009
    ..The authors aimed to explore the efficacy of (90)Yttrium-1,4,7,10-tetra-azacyclododecane N,N',N'',N'''-tetraacetic acid [(90)Y-DOTA]-Tyr(3)-octreotide (TOC) in advanced iodine-refractory thyroid cancer...
  20. ncbi request reprint Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial
    Fabienne Iten
    Institute of Nuclear Medicine, Division of Endocrinology, Diabetology, and Clinical Nutrition, University Hospital Basel, University of Basel, Petersgraben 4, Basel, Switzerland
    Clin Cancer Res 13:6696-702. 2007
    ..We aimed to explore the efficacy of (90)Yttrium-1,4,7,10-tetra-azacyclododecane N,N',N'',N-'''-tetraacetic acid ((90)Y-DOTA)-Tyr(3)-octreotide (TOC) therapy in advanced medullary thyroid cancer...
  21. pmc Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography
    Rachel E Laing
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 106:2847-52. 2009
    ..DCK-negative tumors, and [(18)F]FAC microPET scans can predict responses to dFdC. We suggest that [(18)F]FAC PET might be useful for guiding treatment decisions in certain cancers by enabling individualized chemotherapy...
  22. doi request reprint 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas
    Farzin Imani
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Nucl Med 50:513-9. 2009
    ..Herein, we investigated the accuracy of PET using 3,4-dihydroxy-6-(18)F-fluoro-phenylalanine ((18)F-FDOPA), an amino acid transporter substrate, as an independent marker for detection of benign and malignant pheochromocytomas...
  23. doi request reprint Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Nucl Med 51:1532-8. 2010
    ..The aims of the current study were to determine whether the degree of (18)F-FDOPA uptake in brain tumors predicted tumor grade and was associated with tumor proliferative activity in newly diagnosed and recurrent gliomas...
  24. doi request reprint The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis
    Martin Fuchs
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    Eur J Nucl Med Mol Imaging 39:344-53. 2012
    ..We aimed to assess the impact of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) on the management of patients with suspected large vessel vasculitis...
  25. doi request reprint 99mTc-DPD-SPECT/CT predicts the outcome of imaging-guided diagnostic anaesthetic injections: a prospective cohort study
    Martin Kretzschmar
    Division of Interventional Radiology, University Hospital, Petersgraben 4, CH 4031 Basel, Switzerland
    Eur J Radiol 80:e410-5. 2011
    ..Therefore we prospectively investigated feasibility and predictive value of bone SPECT/CT for image guided diagnostic infiltrations in patients with chronic foot pain...
  26. doi request reprint Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours
    Stephan Good
    Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    Eur J Nucl Med Mol Imaging 35:1868-77. 2008
    ..We used macrocyclic chelators for coupling to increase complex stability, modified the peptide sequence to enhance radiolytic stability and studied tumour-to-kidney ratio and metabolic stability using (111)In-labelled derivatives...
  27. ncbi request reprint Indium-111 labeled gold nanoparticles for in-vivo molecular targeting
    Quinn K T Ng
    Institute of Nuclear Medicine, University Hospital Bern, Bern 3010 CH, Switzerland Department of Clinical Research, University Bern, Bern 3010 CH, Switzerland
    Biomaterials 35:7050-7. 2014
    ..The results demonstrate the vast potential of direct labeling with radioisotopes for tracking gold nanoparticles within biological systems. ..
  28. doi request reprint Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
    Franziska Walter
    Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA
    J Pediatr Hematol Oncol 34:131-6. 2012
    ..It is unknown whether the combination of both tests results in more accurate detection of bone lesions than (18)F-FDG- PET/CT alone...
  29. doi request reprint Prevalence, characteristics, and publication of discontinued randomized trials
    Benjamin Kasenda
    Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel, Basel, Switzerland
    JAMA 311:1045-51. 2014
    ..The discontinuation of randomized clinical trials (RCTs) raises ethical concerns and often wastes scarce research resources. The epidemiology of discontinued RCTs, however, remains unclear...
  30. ncbi request reprint Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Daniel Storch
    Division of Radiological Chemistry, Department of Radiology, University Hospital of Basel, Basel, Switzerland
    J Nucl Med 46:1561-9. 2005
    ..The main attention was directed toward a potential correlation between the rate of internalization and the tumor or pancreas uptake...
  31. ncbi request reprint Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy
    Mihaela Ginj
    Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Clin Cancer Res 11:1136-45. 2005
    ..The aim of this study was to develop novel analogues with a broader sstr profile for diagnostic (positron emission tomography and single-photon emission computed tomography) and radiotherapeutic applications...
  32. doi request reprint Graves' disease
    Martin A Walter
    N Engl J Med 359:1407; author reply 1409. 2008
  33. ncbi request reprint Antithyroid drugs and radioiodine and the absence of evidence
    Martin A Walter
    J Nucl Med 48:1403; author reply 1403-4. 2007
  34. ncbi request reprint Enhancement of radioiodine uptake in hyperthyroidism by administration of hydrochlorothiazide
    Martin A Walter
    Eur J Nucl Med Mol Imaging 30:474. 2003
  35. ncbi request reprint Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1
    Birke Bausch
    Department of Neurology, University Medical Center Freiburg, Germany
    J Clin Endocrinol Metab 92:2784-92. 2007
    ..Because of the low prevalence of pheochromocytoma in NF1, we ascertained subjects by pheochromocytoma that also had NF1 in the hope of describing the germline NF1 mutational spectra of NF1-related pheochromocytoma...